JP7898388B2 - 修飾タンパク質およびタンパク質分解誘導薬 - Google Patents

修飾タンパク質およびタンパク質分解誘導薬

Info

Publication number
JP7898388B2
JP7898388B2 JP2022573579A JP2022573579A JP7898388B2 JP 7898388 B2 JP7898388 B2 JP 7898388B2 JP 2022573579 A JP2022573579 A JP 2022573579A JP 2022573579 A JP2022573579 A JP 2022573579A JP 7898388 B2 JP7898388 B2 JP 7898388B2
Authority
JP
Japan
Prior art keywords
optionally substituted
ddb1
protein
alkyl
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022573579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529099A (ja
JP2023529099A5 (enExample
Inventor
リュー，ジン
ブルーノ プリュー，マイケル
ランドロフ リー，マシュー
ハン，シャオラン
チェン，リチュン
ジャン，チョンウェイ
ワン，ジャリャン
Original Assignee
クルゲン（シャンハイ），インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クルゲン（シャンハイ），インク． filed Critical クルゲン（シャンハイ），インク．
Publication of JP2023529099A publication Critical patent/JP2023529099A/ja
Publication of JP2023529099A5 publication Critical patent/JP2023529099A5/ja
Application granted granted Critical
Publication of JP7898388B2 publication Critical patent/JP7898388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
JP2022573579A 2020-05-28 2021-05-28 修飾タンパク質およびタンパク質分解誘導薬 Active JP7898388B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020092941 2020-05-28
CNPCT/CN2020/092941 2020-05-28
CNPCT/CN2021/081554 2021-03-18
CN2021081554 2021-03-18
PCT/CN2021/096782 WO2021239117A1 (en) 2020-05-28 2021-05-28 Modified proteins and protein degraders

Publications (3)

Publication Number Publication Date
JP2023529099A JP2023529099A (ja) 2023-07-07
JP2023529099A5 JP2023529099A5 (enExample) 2024-06-04
JP7898388B2 true JP7898388B2 (ja) 2026-07-31

Family

ID=78722770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573579A Active JP7898388B2 (ja) 2020-05-28 2021-05-28 修飾タンパク質およびタンパク質分解誘導薬

Country Status (5)

Country Link
US (2) US20230057177A1 (enExample)
EP (1) EP4157888A4 (enExample)
JP (1) JP7898388B2 (enExample)
CN (1) CN116472292A (enExample)
WO (1) WO2021239117A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
WO2022218239A1 (zh) * 2021-04-12 2022-10-20 杜心赟 新型噻唑类化合物及其制备方法和用途
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
AU2022362494A1 (en) * 2021-10-14 2024-05-23 Cullgen (Shanghai), Inc. Modified proteins and protein degraders
US20260209211A1 (en) * 2022-12-16 2026-07-23 Adlai Nortye Biopharma Co., Ltd. Cyclin k degrader and use thereof
CN121358732A (zh) * 2023-03-07 2026-01-16 睿跃生物科技有限公司 治疗癌症的化合物和方法
WO2025054361A1 (en) * 2023-09-05 2025-03-13 Apellis Pharmaceuticals, Inc. Complement inhibition
WO2026128761A1 (en) 2024-12-11 2026-06-18 Nexo Therapeutics, Inc. Covalent p300 inhibitor compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144832A1 (en) 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon
WO2019034332A1 (en) 2017-08-18 2019-02-21 Cambridge Enterprise Limited MODULAR BINDING PROTEINS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008372B2 (en) * 2015-11-07 2021-05-18 Board Of Regents, The University Of Texas System Targeting proteins for degradation
GB201520583D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3864030A4 (en) * 2018-10-12 2022-09-21 The Scripps Research Institute Compounds and methods for dcaf-mediated protein degradation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144832A1 (en) 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon
WO2019034332A1 (en) 2017-08-18 2019-02-21 Cambridge Enterprise Limited MODULAR BINDING PROTEINS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kazuma Sekiba et al.，Cellular and Molecular Gastroenterology and Hepatology，2019年，Vol. 7, No. 2，pp. 297-312

Also Published As

Publication number Publication date
EP4157888A4 (en) 2024-07-10
JP2023529099A (ja) 2023-07-07
US20230057177A1 (en) 2023-02-23
EP4157888A1 (en) 2023-04-05
WO2021239117A1 (en) 2021-12-02
US20240066136A1 (en) 2024-02-29
CN116472292A (zh) 2023-07-21

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260721

R150 Certificate of patent or registration of utility model

Ref document number: 7898388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150